Pharming Launches Joenja in Japan, First Market for Pediatric APDS Patients
PHAR sits 19% above its 52-week low of $9.62 on elevated volume (3.2× avg).
Summary
Pharming launches Joenja in Japan for APDS patients aged 4 and older, marking the first commercial availability for children aged 4 to 11 worldwide.
Key Events · Product Development and Regulatory · PHAR
-
Japan Commercial Launch
Joenja (leniolisib) is now commercially available in Japan for adult and pediatric APDS patients aged 4 and older, following inclusion on the Japan NHI drug price list.
-
First Pediatric Availability
Japan becomes the first market worldwide where Joenja is commercially available for children aged 4 to 11, expanding the addressable patient population.
-
OrphanPacific Partnership
OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution of Joenja in Japan under an agreement with Pharming.
-
Regulatory Milestone
The launch follows Japan's MHLW approval in March 2026, making Joenja the first treatment specifically for APDS in Japan.
Analysis · PHAR · Life Sciences
The commercial launch of Joenja (leniolisib) in Japan marks a significant expansion for Pharming, making the therapy available to adult and pediatric APDS patients aged 4 and older after its inclusion on the Japan National Health Insurance (NHI) drug price list. Notably, Japan becomes the first market worldwide where Joenja is commercially available for children aged 4 to 11, broadening the addressable patient population. OrphanPacific, Inc. holds the Marketing Authorization and manages supply and distribution in Japan. This launch follows Japan's MHLW approval in March 2026 and represents a key commercial milestone in the company's global expansion strategy.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $11.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $818.8M. The 52-week trading range was $9.62 to $21.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.